

Factors influencing adherence to secondary prophylaxis among children and adolescents with Rheumatic Heart Disease at Port Moresby General Hospital and Nonga General Hospital:
A mixed methods study

Dr Veronica Kalit

Master of Medicine candidate 2018

Background

- Acute rheumatic fever (ARF) develops after infection of the throat or skin with Group A Beta Haemolytic Streptococcus - GAS
- GAS infection can result in permanent damage to the valves of the heart, causing rheumatic heart disease (RHD)
- Worldwide ~ 15.6 million people with RHD with ~ 470 000 new cases of ARF annually & 230 000 deaths related to RHD each year

Background

- WHO recommends Benzathine penicillin intramuscular injections 4 -weekly for prevention of GAS
- Compliance with secondary prophylaxis reduces the risk of complications
- Factors such as patients knowledge of ARF/RHD , patient staff interactions and the painful nature of benzathine penicillin injections influence compliance
- Single most important challenge to ARF/RHD programs is the poor uptake and adherence to secondary prophylaxis

Study Aim

- Document patients' and their parents' understanding of rheumatic heart disease and how this influenced their adherence with secondary prophylaxis

Methodology

Study type: Mixed methods study – quantitative and qualitative data

Study sites: PMGH & NGH

Study Time: February 2016 - July 2018

Sample size: 48 patients/ 26 patient interviews

Methodology

Inclusion Criteria:

- Children
 - 5 - 15 years old presenting to PMGH & NGH who fit the 2002–2003 WHO revision of the Jones Criteria for the diagnosis of ARF
 - previously diagnosed with ARF/RHD whose names were on the cardiac register, or were seen in cardiac follow-up clinic
 - on either benzathine penicillin or penicillin V (oral phenoxymethyl penicillin) as secondary prophylaxis

Methodology

Data collection

- Standard ARF & RHD Case Report form completed after verbal consent
- Individual interviews

Data analysis

- Data were entered into Microsoft Excel, and analysed using descriptive epidemiology

Ethical Considerations

- Ethical approval obtained from UPNG SMHS Research Committee as well as PMGH and NGH Administration

Results – baseline characteristics

Variable	Frequency n=48 (%)
Age Median (IQR)	11 years (9 – 13 years)
Gender	
Male	28 (58.33)
Female	20 (41.68)
Residence	
Suburb	22 (45.83)
Settlement	7 (14.58)
Village	19 (39.58)
Presenting Criteria (Major)	
Carditis	35 (72.92)
Migratory polyarthritis	23 (47.92)
Sydenham's Chorea	2 (4.17)
Presenting Criteria (Minor)	
Fever	32 (66.67)
Polyarthralgia or aseptic monoarthritis	5 (10.42)
Prolonged PR interval on ECG	10 (20.83)

Results – echocardiographic findings

Cardiac abnormalities	n = 48	%
Mod – Severe MR	31	64.6
Mod – Severe AR	20	41.7
Mild MR	6	12.5
Mild AR	5	8.3
Trivial MR	0	0.00
Trivial AR	3	6.3
Mild MS	6	12.5
Moderate MS	3	6.3
Severe MS	1	2.1
Normal study	3	6.3
Not done	2	4.2

Results - complications

Complications of Rheumatic Heart Disease

	n= 48	%
Heart Failure	31	64.6
Atrial Fibrillation	0	0.0
Infective Endocarditis	1	2.1
Stroke	1	2.1
None	15	31.3

Heart failure medication for patients in the study population

	n = 31	%
Furosemide	12	38.71
Furosemide, Spironolactone	13	41.94
Furosemide, Spironolactone, Enalapril	5	16.13
Furosemide, Spironolactone, Captopril	1	3.23

Outcomes - deaths

- 4 deaths in the 2 year period of observation (8.3%)
- 2 - Suspected severe anaphylaxis to benzathine penicillin
- 1 - biventricular heart failure
- 1 - stroke

Results – case study

'GR was 12 years old when he was first diagnosed with RHD in late 2015. He lived with his mother and grandmother and was brought to the clinic most of the time by his grandmother. On ECHO he was found to have severe mitral and aortic incompetence with mitral stenosis and had signs of heart failure so he was commenced on monthly benzathine injections and frusemide and spironolactone for his heart failure. Unfortunately he often missed several months of his benzathine injections and antifailure treatment because he was not brought to the clinic.

In March 2017 GR now almost 14 years old, walked from Korobosea to the PMGH paediatric cardiac clinic for his routine monthly benzathine penicillin injection. He had received his benzathine penicillin injections in the previous 7 months with no issues and appeared fine that morning. As soon as he entered the clinic, he was brought to the procedure bed and the nurse administered his injection as usual. GR then made an attempt to get up but suddenly collapsed afterwards. The medical team present attempted to resuscitate him but were unsuccessful'

Changes in practice during the study

- The deaths lead to a change in secondary prophylaxis at PMGH – from predominantly 4-weekly IM benzathine to daily oral penicillin V
- Cause of death and precipitating factors unclear

Results – secondary prophylaxis

Secondary Prophylaxis	Comments by patients and parents	Secondary prophylaxis preference
Benzathine to Penicillin V (n = 19)	<p>(BK M/14): “I prefer monthly injections, its once a month only, It’s hard to remember to take tablets everyday”</p>	<p>Benzathine Penicillin (5, 26.32%)</p>
	<p>Parent of MH:” Even though it’s painful, it’s once a month. Tablets we forget, when we visit relatives, we leave the tablets at home.”</p>	
	<p>(JO F/9): I want to drink medicine, the injections are painful</p>	<p>Penicillin V (5, 26.32%)</p>
	<p>(PA F/11): Both injection or medicine okay</p> <p>Parent of RY: “Both are okay. Injections never did any harm.”</p>	<p>Either (6, 31.58%)</p>
		<p>Neither (3, 15.79%)</p>

Results – secondary prophylaxis

Secondary Prophylaxis	Comments of Patients	Number of Benzathine Doses Missed
Benzathine only (n = 5)	<p>(KP M/11) “I don’t mind the injections, it’s painful but its once a month. I won’t be able to remember to take tablets everyday”</p> <p>(HP F/8): “I want to drink tablets, the injections are painful. I don’t like it when the injection is blocked and the nurse tries many times”</p> <p>(DT M/13) “I want the tablets, the injections are painful”</p>	<p>2 (0 missed doses)</p> <p>2(< 3 missed doses)</p> <p>1(> 3 missed doses)</p>

Results – secondary prophylaxis

- Preference
 1. Penicillin V (9, 34.6%)
 2. Benzathine Penicillin (8, 30.8%)
 3. Either (6, 23.1%)
 4. Neither (3, 11.5%)
- Factors influencing compliance
 - Benzathine injections painful
 - Forget to take Penicillin V everyday

Results – school participation

School attendance	n = 48	%
Fulltime (miss for reviews only)	17	35.4
Misses some days	7	14.6
Misses several days/weeks	2	4.2
Not attending	21	43.8
Not known	1	2.1

Results – school participation

Parents Comments on School Participation

**Not Attending
(n=11)**

(PAs MUM): She has had several admissions because of her illness. I worry something will happen to her if she goes to school.

NMs DAD: “The teacher told us to keep him at home first because he didn’t look well”

**Misses some
days
(n = 4)**

(KPs MUM): “He stopped going to school, because he was always unwell. Since getting his injection he is better. He went back to school this year but he has had to repeat a grade”.

Discussion

- Low level of awareness of ARF/RHD
- Severe valvular lesions in a very young cohort
 - Nicaragua: Population screening used on 3150 children > children identified with RHD had mild carditis
- Poor school attendance
 - 40 % children not attending school → poor academic performance → economic & socio-developmental consequences

Discussion – Benzathine Penicillin?

- WHO recommends 4 weekly Benzapen injections as prophylaxis against GAS
- Compliance with daily oral penicillin V a problem
- Systemic review comparing the effectiveness of intramuscular penicillin and oral penicillin > very strong evidence for im penicillin
 - 87 – 96% reduction in RF recurrence
 - 71 – 91% reduction in streptococcal throat infection

Discussion - Safety of Benzathine Pen

- Widely used for the prevention of recurrent RF for several years , reports of fatal reactions rare
- 1962 report on 3 cases that had fatal reactions to Benzapen all had cardiomegaly and a history of cardiac decompensation
- Children with severe heart failure or arrhythmias possibly more risk of sudden death than children with milder disease
- No reason to believe that Benzapen poses a risk for the vast majority of RHD patients

Limitations

- Small sample size
- Hospital based study most likely to describe patients with more advanced RHD

Conclusion

- Rheumatic heart disease is a cause of significant morbidity and mortality in children and adolescents presenting to PMGH & NGH
- Patients often have advanced disease pattern which is a reflection of a high burden of ARF and RHD in the community, late presentation and likely poor secondary prophylaxis adherence.

Recommendation

- Increase awareness
- Active detection for RHD using population screening
- Role of benzathine penicillin in secondary prophylaxis needs to be made clear, so that the RHD program can be optimally effective

Acknowledgement

- Dr Cornelia Kilalang
- Dr Beryl Vetuna
- Prof Trevor Duke
- PMGH & NGH Registrars
- PMGH & NGH Consultation clinic Nursing staff
- All the children, their families who participated in this study

References

1. RHD Australia (ARF/RHD writing group), National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Australian guidelines for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition). 2012
2. Carapetis, J.R., et al., *The global burden of group A streptococcal diseases*. Lancet Infect Dis, 2005. 5(11): p. 685-94.
3. Mincham CM, et al. *Patient views on the management of rheumatic fever and rheumatic heart disease in the Kimberley: a qualitative study*. Aust J Rural Health. 2003 Dec; 11(6): 260-5
4. Ludwane, B. (2017) *Acute Rheumatic Fever/Rheumatic Heart Disease: Patients/parents and Nurses knowledge to the disease and adherence to benzathine penicillin prophylaxis* . (Unpublished master's thesis). University of Papua New Guinea, Papua New Guinea.
5. Seckeler, M. D., & Hoke, T. R. (2011). The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease. *Clinical Epidemiology*, 3, 67–84.
6. Manyemba J, Mayosi B. Intramuscular penicillin is more effective than oral penicillin in secondary prevention of rheumatic fever – a systemic review. March 2003 , Vol. 93. No.3 SAMJ.
7. John A. Paar, Nubia M. Berrios et al. Prevalence of Rheumatic Heart Disease in Children and Young Adults in Nicaragua. AM J Cardiol 2010;105: 1809-1814.
8. Steigmann F and JR Suker. *Fatal reactions to Benzathine Penicillin G, Report of Three Cases and Discussion of Contributory Factors*. JAMA Jan 27 1962.
9. Nordet P, Lopez R, Dueñas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986e1996e2002). Cardiovasc J Afr 2008;19:135–40.